Frederick Tam

Prof. Frederick Tam

Department of Immunology and Inflammation, Imperial College London, London, City of London, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2011 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
NANishkantha Arulkumaran
Nishkantha Arulkumaran
RURobert J Unwin
Robert J Unwin
FTFrederick Tam
Frederick Tam
(2011). A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opinion on Investigational Drugs: Vol. 20, No. 7, pp. 897-915.

1 June 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
STSimon R.J. Taylor
Simon R.J. Taylor
CTClare M. Turner
Clare M. Turner
JEJames I. Elliott
James I. Elliott
JMJohn McDaid
John McDaid
RHReiko Hewitt
Reiko Hewitt
FTFrederick Tam
Frederick Tam
The P2X7 receptor is a ligand-gated cation channel that is normally expressed by a variety of immune cells, including macrophages and lymphocytes. Because it leads to membrane blebbing, release of IL-1β, and cell death by apoptosis or necrosis, it is a potential therapeutic target for a variety of inflammatory diseases. Although the P2X7 receptor is usually not detectable in normal renal tissue, we previously reported increased expression of both mRNA and protein in mesangial cells and macrophages infiltrating the glomeruli in animal models of antibody-mediated glomerulonephritis. In this study, we used P2X7-knockout mice in the same experimental model of glomerulonephritis and found that P2X7 deficiency was significantly renoprotective compared with wild-type controls, evidenced by better renal function, a striking reduction in proteinuria, and decreased histologic glomerular injury. In addition, the selective P2X7 antagonist A-438079 prevented the development of antibody-mediated glomerulonephritis in rats. These results support a proinflammatory role for P2X7 in immune-mediated renal injury and suggest that the P2X7 receptor is a potential therapeutic target.

7 September 2004 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
FTFrederick Tam
Frederick Tam
JSJan-Stephan Sanders
Jan-Stephan Sanders
AGAbraham George
Abraham George
THTarig Hammad
Tarig Hammad
CMCaroline Miller
Caroline Miller
CPCharles D. Pusey
Charles D. Pusey
Background. Macrophage infiltration and cytokine production are important in the pathogenesis of crescentic glomerulonephritis in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. The aim of this study was to investigate whether urinary levels of chemokines, monocyte chemoattractant protein-1 (MCP-1) and fractalkine, were useful tools for non-invasive assessment of renal vasculitis. Methods. In a prospective study, concentrations of chemokines were measured in urine and serum samples using specific enzyme-linked immunosorbent assays, and related to the patients’ clinical status. Renal expression of MCP-1 was studied by immunohistochemical staining of renal biopsies. Results. Urinary levels of MCP-1 were significantly higher in patients with active (P<0.01) or persistent (P<0.05) renal vasculitis, in comparison with healthy volunteers, control patients, patients with inactive vasculitis and patients with extra-renal disease only. There were no differences in serum concentrations of MCP-1 between these groups. Reduction in urinary MCP-1 levels following treatment preceded the improvement of renal function by a median of 2 weeks. In one patient, rising urinary levels of MCP-1, despite immunosuppressive therapy, was associated with progression to severe renal failure. There were no differences in urinary fractalkine levels between the different groups of patients and controls. Immunohistology of renal biopsies from patients with crescentic glomerulonephritis showed increased staining for MCP-1 in glomerular and interstitial cells. Urinary MCP-1 levels correlated with glomerular, but not tubulointerstitial, macrophage infiltration (P<0.05). Conclusions. This study shows that measurement of urinary MCP-1, but not fractalkine, is a useful non-invasive technique for the assessment of renal involvement and monitoring the response to therapy in ANCA-associated vasculitis.

1 July 2009 in Cytokine
Verified
Journal Article
Closed access
FTFrederick Tam
Frederick Tam
BRBruce L. Riser
Bruce L. Riser
KMKarim Meeran
Karim Meeran
JRJoAnn Rambow
JoAnn Rambow
CPCharles D. Pusey
Charles D. Pusey
AFAndrew H. Frankel
Andrew H. Frankel

23 January 2014 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
CTClare M Turner
Clare M Turner
NANishkantha Arulkumaran
Nishkantha Arulkumaran
MSMervyn Singer
Mervyn Singer
RURobert J Unwin
Robert J Unwin
FTFrederick Tam
Frederick Tam
The inflammasome is a large, multiprotein complex that drives proinflammatory cytokine production in response to infection and tissue injury. Pattern recognition receptors that are either membrane bound or cytoplasmic trigger inflammasome assembly. These receptors sense danger signals including damage-associated molecular patterns and pathogen-associated molecular patterns (DAMPS and PAMPS respectively). The best-characterized inflammasome is the NLRP3 inflammasome. On assembly of the NLRP3 inflammasome, post-translational processing and secretion of pro-inflammatory cytokines IL-1β and IL-18 occurs; in addition, cell death may be mediated via caspase-1. Intrinsic renal cells express components of the inflammasome pathway. This is most prominent in tubular epithelial cells and, to a lesser degree, in glomeruli. Several primary renal diseases and systemic diseases affecting the kidney are associated with NLRP3 inflammasome/IL-1β/IL-18 axis activation. Most of the disorders studied have been acute inflammatory diseases. The disease spectrum includes ureteric obstruction, ischaemia reperfusion injury, glomerulonephritis, sepsis, hypoxia, glycerol-induced renal failure, and crystal nephropathy. In addition to mediating renal disease, the IL-1/ IL-18 axis may also be responsible for development of CKD itself and its related complications, including vascular calcification and sepsis. Experimental models using genetic deletions and/or receptor antagonists/antiserum against the NLRP3 inflammasome pathway have shown decreased severity of disease. As such, the inflammasome is an attractive potential therapeutic target in a variety of renal diseases.

1 February 2010 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JSJennifer Smith
Jennifer Smith
JMJohn P. McDaid
John P. McDaid
GBGurjeet Bhangal
Gurjeet Bhangal
RCRatana Chawanasuntorapoj
Ratana Chawanasuntorapoj
EMEsteban S. Masuda
Esteban S. Masuda
FTFrederick Tam
Frederick Tam
Antibody-mediated glomerulonephritis, including that resulting from immune complexes, is an important cause of renal failure and is in need of more specific and effective treatment. Binding of antibody or immune complexes to Fc receptors activates intracellular signal transduction pathways, including spleen tyrosine kinase (Syk), leading to the production of inflammatory cytokines. We examined the effect of R788 (fostamatinib disodium), an oral prodrug of the selective Syk inhibitor R406, in nephrotoxic nephritis in Wistar-Kyoto rats. Treatment with R788 reduced proteinuria, tissue injury, glomerular macrophage and CD8+ cell numbers, and renal monocyte chemoattractant protein-1 (MCP-1) and IL-1β, even when we started treatment after the onset of glomerulonephritis. When we administered R788 from days 4 to 10, glomerular crescents reduced by 100% (P < 0.01) compared with the vehicle group. When we administered R788 treatment from days 7 to 14, established glomerular crescents reversed (reduced by 21%, P < 0.001), and renal function was better than the vehicle group (P < 0.001). In vitro, R406 downregulated MCP-1 production from mesangial cells and macrophages stimulated with aggregated IgG. These results suggest that Syk is an important therapeutic target for the treatment of glomerulonephritis.